BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Metabolic dysfunction-associated steatohepatitis
1
Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study
1/27/2026 10:12:31 AM | Browse: 35 | Download: 118
2
Histone lactylation: A key epigenetic modulator in the pathogenesis of metabolic dysfunction-associated steatohepatitis and alcoholic steatohepatitis
12/26/2025 10:27:29 AM | Browse: 52 | Download: 166
3
Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease
12/19/2025 10:39:41 AM | Browse: 67 | Download: 274
4
Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis
12/10/2025 7:48:07 AM | Browse: 112 | Download: 278
5
Endoscopic sleeve gastrectomy vs traditional bariatric surgery: A paradigm shift in managing metabolic dysfunction-associated steatohepatitis and cirrhosis?
12/5/2025 11:28:05 AM | Browse: 79 | Download: 212
6
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
12/5/2025 11:28:02 AM | Browse: 79 | Download: 194
7
Impact of alcohol-associated and metabolic dysfunction-associated steatotic liver diseases upon hepatic disorder and carcinogenesis in the current era
11/27/2025 7:53:59 AM | Browse: 66 | Download: 209
8
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis
11/27/2025 7:53:58 AM | Browse: 66 | Download: 265
9
Noninvasive prediction of clinically significant portal hypertension in metabolic dysfunction-associated steatotic liver disease compared to other chronic liver diseases
9/25/2025 11:24:06 AM | Browse: 94 | Download: 123
10
Extracellular vesicles in metabolic dysfunction-associated steatotic liver disease: From intercellular signaling to clinical translation
9/25/2025 11:24:01 AM | Browse: 129 | Download: 261
11
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review
9/25/2025 3:33:08 AM | Browse: 104 | Download: 205
12
Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review
9/4/2025 7:48:05 AM | Browse: 437 | Download: 283
13
Heterogeneous outcomes in metabolic dysfunction–associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches
8/28/2025 9:39:08 AM | Browse: 470 | Download: 394
14
Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease
5/27/2025 7:04:47 AM | Browse: 70 | Download: 485
15
Risks of liver cirrhosis, hepatocellular carcinoma, hepatic-related complications, and mortality in patients with type 2 diabetes in Taiwan
4/25/2025 7:54:04 AM | Browse: 127 | Download: 702
16
Association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis: From an analysis of a population-based study
2/20/2025 8:38:48 AM | Browse: 39 | Download: 147
17
Helicobacter pylori infection as a contributing factor to metabolic dysfunction-associated steatohepatitis: A population-based insight
1/6/2025 8:47:59 AM | Browse: 184 | Download: 729
18
Potential mechanisms and therapeutic prospects of the association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis
1/6/2025 8:47:55 AM | Browse: 172 | Download: 807
19
Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model
11/29/2024 2:50:18 PM | Browse: 154 | Download: 1130
20
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
11/29/2024 8:40:08 AM | Browse: 118 | Download: 476
21
Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease
11/26/2024 7:20:28 AM | Browse: 186 | Download: 639
22
Prevalence and risk factors associated with metabolic dysfunction-associated steatohepatitis in patients with Helicobacter pylori infection: A population-based study
10/21/2024 7:03:25 AM | Browse: 110 | Download: 579
23
Predictive value of serum alanine aminotransferase for fatty liver associated with metabolic dysfunction
7/26/2024 10:33:29 AM | Browse: 198 | Download: 825
24
Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease
6/21/2024 3:14:32 AM | Browse: 184 | Download: 640
25
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
5/22/2024 11:33:24 AM | Browse: 125 | Download: 571
26
Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study
5/10/2024 11:51:40 AM | Browse: 169 | Download: 1032
27
De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
12/27/2021 5:24:00 AM | Browse: 740 | Download: 1584
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345